References
- Alemohammad H, Najafzadeh B, Asadzadeh Z, et al. The importance of immune checkpoints in immune monitoring: a future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2022;146:112516.
- Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105–115.
- Catalán D, Mansilla MA, Ferrier A, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795.
- Huang P-W, Chang JW-C. Immune checkpoint inhibitors win the 2018 Nobel Prize. Biomed J. 2019;42(5):299–306.
- Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):1–3.
- Food U, Administration D. Pembrolizumab (Keytruda) for classical Hodgkin lymphoma. 2017, FDA site:https://www.fda.gov/.
- Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419–3427.
- Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393–1405.
- Fillatreau S. Natural regulatory plasma cells. Curr Opin Immunol. 2018;55:62–66.
- Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4(7):1367–1377.
- Bae J, Accardi F, Hideshima T, et al. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022;36(1):138–154.
- Gould C, Lickiss J, Kankanige Y, et al. Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. Br J Haematol. 2021;195(1):113–118.
- Behdad A, Schipma MJ, Ma S, et al. Distinct immune-response profile of Richter transformation of chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10. Leuk Lymph. 2022;1–5, DOI: 10.1080/10428194.2022.2123236.